More than 90% of breast cancer patients are diagnosed at an early stage. While some of those with hormone receptor positive (HR+) do not have local or distant recurrence when treated with conventional therapies, more than 30% whose cancer has high-risk clinical or pathological features may experience distant recurrence, many of them in the first two years. years old. Therefore, new treatment options are more than necessary to prevent early recurrences and the development of metastases.
Abemaciclib is an oral drug that inhibits the action of CDK 4/6 cyclin-dependent kinases, approved for use in patients with advanced HER2-, HR+ breast cancer. Its efficacy and safety were evaluated in monarchE, an open-label, phase III study that included high-risk (HR+, HER2-) patients who completed primary treatment. They were randomized to the abemaciclib plus hormone therapy (HT) arm versus HT alone.
“This work demonstrated that the combination of abemaciclib and hormone therapy led to a significant decline in the risk of recurrence and death from breast cancer compared with HT alone in high-risk patients”, comments clinical oncologist Geraldine Eltz de Lima, from the Oncoclínicas Porto Alegre (RS), from the Oncoclínicas Group. Andreza Karine de Barros Almeida Souto, clinical oncologist at Clínica Oncovida (Federal District), which is part of the Oncoclínicas Group, recalls that at the moment there is still no authorization to change the protocols used in clinical practice: “The monarchE needs a follow-up longer to know whether the benefit presented will be sustained, as well as the opening of the overall survival data.”
Visit our website and learn all the details of the monarchE study.